首页> 美国卫生研究院文献>Advances in Virology >Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?
【2h】

Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

机译:在科威特的肾移植患者中巨细胞病毒是否会在抗病毒预防和治疗后产生耐药性?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The resistance of cytomegalovirus (CMV) to ganciclovir or valganciclovir is a factor in therapeutic failure and disease progression. CMV strains resistant to ganciclovir or valganciclovir have been associated with specific mutations in the UL97 and UL54 genes. Sequencing of both CMV UL97 and UL54 genes was performed to detect the presence of CMV antiviral resistance in six patients who received ganciclovir (and/or valganciclovir) and had prolonged detectable CMV DNA in their blood during antiviral treatment. Sequencing results showed no specific mutations in either UL97 or UL54 gene of CMV and therefore the CMV strains in kidney transplant patients who received ganciclovir either prophylactically or therapeutically were from the wild type. Our results suggest that CMV management and immunosuppression protocols for kidney transplant patients followed in the Organ Transplant Centre, Kuwait, is very effective in reducing the opportunity of developing CMV antiviral resistance.
机译:巨细胞病毒(CMV)对更昔洛韦或缬更昔洛韦的耐药性是治疗失败和疾病进展的一个因素。抗更昔洛韦或缬更昔洛韦的CMV毒株已与UL97和UL54基因中的特定突变相关。对CMV UL97和UL54基因进行测序,以检测接受更昔洛韦(和/或缬更昔洛韦)治疗且在抗病毒治疗期间血液中可检测到CMV DNA延长的六名患者中CMV抗病毒耐药性的存在。测序结果表明,CMV的UL97或UL54基因均无特异性突变,因此,接受预防性或治疗性更昔洛韦治疗的肾移植患者的CMV株均来自野生型。我们的结果表明,在科威特的器官移植中心进行的肾脏移植患者的CMV管理和免疫抑制方案在减少发展CMV抗病毒耐药性的机会方面非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号